Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

570
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Routine venoarterial extracorporeal membrane oxygenation for acute myocardial infarction-related cardiogenic shock: what we know and don't know.

Intensive care medicine·2024
Same author

Ventricular septal defect complicating acute myocardial infarction: diagnosis and management. A Clinical Consensus Statement of the Association for Acute CardioVascular Care (ACVC) of the ESC, the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC and the ESC Working Group on Cardiovascular Surgery.

European heart journal·2024
Same author

Impact of Blood Pressure Targets in Patients With Heart Failure Undergoing Postresuscitation Care: A Subgroup Analysis From a Randomized Controlled Trial.

Circulation. Heart failure·2024
Same author

Vasodilators for Acute Heart Failure - A Systematic Review with Meta-Analysis.

NEJM evidence·2024
Same author

Biomarker patterns in patients with cardiogenic shock versus septic shock.

International journal of cardiology. Heart & vasculature·2024
Same author

Acute kidney injury after out-of-hospital cardiac arrest.

Critical care (London, England)·2024

相关实验视频

Updated: Jun 24, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.2K

心脏性休克研究的未来

Jacob Eifer Møller1,2, Holger Thiele3, Christian Hassager1,4

  • 1Department of Cardiology, Copenhagen University Hospital, Copenhagen.

Current opinion in critical care
|June 6, 2024
PubMed
概括

未来对心脏性休克的研究将利用人工智能和机器学习来确定患者的表型. 新的试验设计将解决治疗这种关键疾病的挑战.

更多相关视频

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.6K
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

712

相关实验视频

Last Updated: Jun 24, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.2K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.6K
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

712

科学领域:

  • 心脏病学 心脏病学
  • 医学研究 医学研究
  • 临床试验 临床试验

背景情况:

  • 心脏性休克是一种危及生命的疾病,在研究和治疗方面存在复杂的挑战.
  • 患者群体的异质性使临床试验设计和结果的解释变得复杂.
  • 伦理考虑,包括知情同意和及时干预,对急性环境中的研究构成重大障碍.

研究的目的:

  • 概述心脏性休克的未来研究方向.
  • 讨论研究这种疾病的创新研究设计.
  • 突出了解和管理心脏性休克的进展.

主要方法:

  • 关于心脏性休克研究的当前文献的综述.
  • 探索人工智能 (AI) 和机器学习 (ML) 用于患者表型化.
  • 讨论分子机制发现的蛋白质和代谢学方法.
  • 机械循环支持和抗炎策略的分析.
  • 对自适应平台试验设计的评估.

主要成果:

  • 心脏性休克研究受到患者异质性和道德复杂性的阻碍.
  • 人工智能和机器学习为精确的患者表型定型提供了潜力.
  • 蛋白质组学和代谢组学可以阐明潜在的分子通路.
  • 机械循环支持和炎症向是未来的关键研究领域.
  • 适应性平台试验是未来临床研究的一个有希望的方法.

结论:

  • 使用AI/ML进行先进的表型鉴定对于未来的心脏病性休克研究至关重要.
  • 通过蛋白质学和代谢学研究分子机制将增强理解.
  • 专注于机械循环支持和炎症调节是有必要的.
  • 新的试验设计,如适应性平台试验,对于高效的研究至关重要.
  • 解决异质性和道德挑战是推进心脏性休克治疗的关键.